Search Results - "King, Gentry"

The Treatment Landscape of Advanced Hepatocellular Carcinoma by Wong, Kit Man, King, Gentry G., Harris, William P.

“…Purpose of review The systemic treatment of advanced hepatocellular carcinoma (HCC) has significantly evolved. Immune checkpoint inhibitors (ICIs) have…”
Get full text

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors by King, Gentry T., Eaton, Keith D., Beagle, Brandon R., Zopf, Christopher J., Wong, Gilbert Y., Krupka, Heike I., Hua, Steven Y., Messersmith, Wells A., El-Khoueiry, Anthony B.

“…Summary Purpose and Methods Trop-2 is a glycoprotein over-expressed in many solid tumors but at low levels in normal human tissue, providing a potential…”
Get full text

Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma by Coveler, Andrew L, Pillarisetty, Venu G, Koh, Wui-Jin, Zhen, David B, Park, James O, King, Gentry G, Sham, Jonathan G, Hannan, Lindsay M, Mann, Gary N, Baker, Kelsey K, Redman, Mary W, Swanson, Paul E, Chiorean, E Gabriela, Whiting, Sam H

“…Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the United States. Most patients who undergo resection develop…”
Get full text

Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung by Noonan, Sinead A, Patil, Tejas, Gao, Dexiang, King, Gentry G, Thibault, Jessica R, Lu, Xian, Bunn, Paul A, Doebele, Robert C, Purcell, W Thomas, Barón, Anna E, Camidge, D Ross

“…The role of serum tumor markers in the modern management of advanced NSCLC remains poorly described. A single-center retrospective analysis of available…”
Get more information

Successful treatment of disseminated Rosai-Dorfman disease with siltuximab by Lee, Hannah, King, Gentry, Garg, Kavita, Pan, Zenggang, Tobin, Jennifer, Robinson, William A

Get full text

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study by Harding, James J, Fan, Jia, Oh, Do-Youn, Choi, Hye Jin, Kim, Jin Won, Chang, Heung-Moon, Bao, Lequn, Sun, Hui-Chuan, Macarulla, Teresa, Xie, Feng, Metges, Jean-Phillippe, Ying, Jie'er, Bridgewater, John, Lee, Myung-Ah, Tejani, Mohamedtaki A, Chen, Emerson Y, Kim, Dong Uk, Wasan, Harpreet, Ducreux, Michel, Bao, Yuanyuan, Boyken, Lisa, Ma, Jiafang, Garfin, Phillip, Pant, Shubham, Abou-Alfa, Ghassan, Alfonso, Jorge Adeva, Aglietta, Massimo, Baron, Ari, Beg, Muhammad, Aguirre, Paula Carrasco, Chen, Eric, Cheng, Ying, Gracián, Antonio Cubillo, Dahan, Laetitia, De Braud, Filippo, Fenocchio, Elisabetta, Gbolohon, Olumide, Gillmore, Roopinder, Jary, Marine, Javle, Milind, Jiang, Yixing, Kang, Jung Hun, King, Gentry George, Kundranda, Madappa, Layos, Laura, Li, Daneng, Liang, Tingbo, Lonardi, Sara, Marathe, Omkar, Mondaca, Sebastian, Martin, Andrés J. Muñoz, Park, Joon Oh, Pazo Cid, Roberto, Fernandez, Paula Ribera, Rimassa, Lorenza, Alonso, Rosa Rodriguez, Sadeghi, Saeed, Scott, Aaron, Tan, Benjamin, Tougeron, David, Yan, Qiang, Yin, Xiaoyu, Zhao, Haitao

“…HER2 is overexpressed or amplified in a subset of biliary tract cancer. Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited…”
Get full text

FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma by King, Gentry, Javle, Milind

“…Purpose of Review Cholangiocarcinoma is an aggressive cancer with a poor prognosis and limited treatment. Gene sequencing studies have identified genetic…”
Get full text

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors by Javle, Milind, King, Gentry, Spencer, Kristen, Borad, Mitesh J

“…Abstract Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most…”
Get full text

Trial in progress: A feasibility study of multi-platform profiling using biospecimens from patients with resected biliary tract cancer by Diehl, Adam, Harris, William Proctor, King, Gentry Teng

“…Abstract only TPS359 Background: Biliary tract cancers (BTC) are rare malignancies with a high recurrence rate after resection of localized disease…”
Get full text

Combining immunotherapy and radiotherapy in hepatocellular carcinoma: the importance of irradiated tumor burden and the possible role of a low dose radiotherapy induction strategy by Grassberger, Clemens, King, Gentry, Apisarnthanarax, Smith

Get full text

Abstract 3649: Significance of HIV viral load and CD4 count on Kaposi sarcoma in the era of highly active antiretroviral therapy by King, Gentry T., Garg, Shivani

“…Background: Approximately 20% of patients with HIV will have Kaposi Sarcoma (KS) and about half will die within 3 months of diagnosis. Incidence and outcomes…”
Get full text

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World by King, Gentry, Ittershagen, Stacie, He, Luyang, Shen, Ying, Li, Frank, Villacorta, Reginald

“…Introduction Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a common cancer with poor survival outcomes. Although treatment options are limited,…”
Get full text

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations by Li, Daneng, Chen, Eric Xueyu, Hu, Zishuo Ian, Hsieh, David, Hwang, Jimmy J., Feun, Lynn G., Franses, Joseph Wang, King, Gentry Teng, Drake, Thomas, Suzuki, Toshiyasu, Bird, Thomas G, Horrigan, Stephen, Chang, Jean, Stenehjem, David D., Cunningham, Casey

“…TPS4192 Background: β-catenin mutations are present in up to 40% of aHCC pts. Elevated nuclear β-catenin expression levels correlate with poor responses to…”
Get full text

Genomic and immune landscape of biliary tract cancers with ARID1A , PBRM1 , and BAP1 alterations by King, Gentry Teng, Berg, Rachel, Yilma, Binyam, Stoppler, Melissa Conrad, Hsieh, Ronan Wenhan, Safyan, Rachael A, Zhen, David Bing, Coveler, Andrew L., Cohen, Stacey A., Shankaran, Veena, Chiorean, E. Gabriela, Harris, William Proctor

“…557 Background: Alterations in ARID1A, PBRM1 and BAP1 subunits of the SWI/SNF complex are common in biliary tract cancers (BTCs) and have been implicated in…”
Get full text

Finding a role for cancer vaccines in pancreatic cancer: a model of resilience by King, Gentry, Green, Steven, Chiorean, E. Gabriela

Get full text

Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR T MSLN ) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA) by Chiorean, E. Gabriela, Chapuis, Aude, Coveler, Andrew L., Yeung, Cecilia CS, Gooley, Ted, Zhen, David Bing, King, Gentry Teng, Hannan, Lindsay Marie, Cohen, Stacey A., Safyan, Rachael A, Germani, Anthony, Ra, Susan, Casserd, Jennifer, Schmitt, Thomas, Greenberg, Philip D

“…TPS779 Background: PDA has a low tumor mutational burden and an immunosuppressive microenvironment. Targeting overexpressed self-antigens with adoptive,…”
Get full text

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas by Diehl, Adam C, Hannan, Lindsay M, Zhen, David B, Coveler, Andrew L, King, Gentry, Cohen, Stacey A, Harris, William P, Shankaran, Veena, Wong, Kit M, Green, Steven, Ng, Natasha, Pillarisetty, Venu G, Sham, Jonathan G, Park, James O, Reddi, Deepti, Konnick, Eric Q, Pritchard, Colin C, Baker, Kelsey, Redman, Mary, Chiorean, E Gabriela

“…KRAS variant alleles may have differential biological properties which impact prognosis and therapeutic options in pancreatic ductal adenocarcinomas (PDA). We…”
Get full text

Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers by Kasi, Pashtoon Murtaza, Budde, Griffin, Dayyani, Farshid, Botta, Gregory P., Diehl, Adam, King, Gentry Teng, Malla, Midhun, Abdelrahim, Maen, Hanna, Diana L., Schafer, Liudmila N., Tejani, Mohamedtaki Abdulaziz, Krainock, Michael, Billings, Paul R., Olshan, Perry, Aushev, Vasily N., Aleshin, Alexey

“…Abstract only 4103 Background: Hepatocellular carcinoma (HCC) and biliary tract cancers [BTC - including cholangiocarcinoma (CCA) and gall bladder cancers…”
Get full text

The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible? by Oba, Atsushi, Lieu, Christopher Hanyoung, Meguid, Cheryl Lauren, Davis, Sarah Lindsey, Leal, Alexis Diane, Purcell, Tom, King, Gentry Teng, Goodman, Karyn A., Schefter, Tracey E., Gleisner, Ana Luiza, Ahrendt, Steven Arthur, Leong, Stephen, Messersmith, Wells A., Shulick, Richard D., Del Chiaro, Marco

“…Abstract only 685 Background: For borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC), neoadjuvant (NAT) FOLFIRINOX or gemcitabine plus…”
Get full text

An assessment of dose intensity of the TNT approach on outcomes in locally advanced rectal cancer by Glode, Ashley Elizabeth, Friedrich, Tyler, Sandhu, Gurprataap Singh, Herter, Whitney, McCarter, Martin, Gleisner, Ana Luiza, Birnbaum, Elisa, Ahrendt, Steven Arthur, Vogel, Jon, Goodman, Karyn A., Schefter, Tracey E., Purcell, William T., Leal, Alexis Diane, King, Gentry Teng, Davis, S. Lindsey, Leong, Stephen, Messersmith, Wells A., Lieu, Christopher Hanyoung

“…Abstract only 258 Background: Patients with clinical stage II or III locally advanced rectal cancer may be treated with the total neoadjuvant therapy (TNT)…”
Get full text